Fig. 1From: Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapyFlow of sample selection and dropout: Most invalidated samples were due to insufficient tumor cell content. A minimum content of 20% was applied in line with MammaTyper® published specifications [15]Back to article page